Treace Medical Concepts Stock Price, News & Analysis (NASDAQ:TMCI) $9.08 +0.40 (+4.61%) (As of 01:39 PM ET) Add Compare Share Share Today's Range$8.80▼$9.3750-Day Range$6.03▼$13.8952-Week Range$5.27▼$27.97Volume265,862 shsAverage Volume547,950 shsMarket Capitalization$560.05 millionP/E RatioN/ADividend YieldN/APrice Target$18.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Treace Medical Concepts MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside104.5% Upside$18.92 Price TargetShort InterestBearish8.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.79) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.48 out of 5 starsMedical Sector321st out of 949 stocksSurgical & Medical Instruments Industry45th out of 96 stocks 4.4 Analyst's Opinion Consensus RatingTreace Medical Concepts has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.92, Treace Medical Concepts has a forecasted upside of 104.5% from its current price of $9.25.Amount of Analyst CoverageTreace Medical Concepts has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.63% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Treace Medical Concepts has recently decreased by 2.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMCI. Previous Next 2.5 News and Social Media Coverage News SentimentTreace Medical Concepts has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.Search Interest4 people have searched for TMCI on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.Percentage Held by Insiders28.69% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.85% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.79) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -11.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -11.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Treace Medical Concepts Stock (NASDAQ:TMCI)Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.Read More TMCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMCI Stock News HeadlinesNovember 27, 2023 | markets.businessinsider.comRyan Zimmerman Reaffirms Buy Rating on Treace Medical Concepts Amid Anticipated FY24 Rebound and Strategic Growth InitiativesNovember 26, 2023 | americanbankingnews.comTreace Medical Concepts (NASDAQ:TMCI) Sees Large Volume IncreaseNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 24, 2023 | morningstar.comTreace Medical Concepts Inc TMCINovember 24, 2023 | americanbankingnews.comBrokerages Set Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target at $18.92November 12, 2023 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | benzinga.comTreace Medical Concepts Stock (NASDAQ:TMCI), Analyst Ratings, Price Targets, PredictionsNovember 10, 2023 | marketwatch.comTreace Medical Shares Hit All-Time Low After Outlook CutNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 10, 2023 | finance.yahoo.comQ3 2023 Treace Medical Concepts Inc Earnings CallNovember 9, 2023 | markets.businessinsider.comTreace Medical Concepts Disappoints On Q3 Results, Lowers FY23 GuidanceNovember 9, 2023 | finance.yahoo.comTreace Medical Concepts Reports Third Quarter 2023 Financial ResultsOctober 30, 2023 | finance.yahoo.comTreace to Present at Stifel 2023 Healthcare ConferenceOctober 28, 2023 | seekingalpha.comTMCI Treace Medical Concepts, Inc.October 27, 2023 | seekingalpha.comTreace Medical Concepts Continues Growth Investments Despite High Operating LossesOctober 16, 2023 | finance.yahoo.comTreace to Report Third Quarter 2023 Financial ResultsSeptember 29, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Treace Medical ConceptsSeptember 20, 2023 | finance.yahoo.comTreace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023September 17, 2023 | fool.comTreace Medical Concepts (NASDAQ: TMCI)September 14, 2023 | finance.yahoo.comTreace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. PatentSeptember 11, 2023 | finance.yahoo.comTreace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related ProceduresAugust 22, 2023 | finance.yahoo.comTreace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare ConferenceAugust 21, 2023 | finance.yahoo.comTreace Medical Concepts Appoints Nathan Minnich as Senior Vice President, MarketingAugust 11, 2023 | nasdaq.comStephens & Co. Maintains Treace Medical Concepts (TMCI) Equal-Weight RecommendationAugust 10, 2023 | nasdaq.comTruist Securities Maintains Treace Medical Concepts (TMCI) Buy RecommendationAugust 9, 2023 | seekingalpha.comTreace Medical Concepts Non-GAAP EPS of -$0.20, revenue of $42MAugust 9, 2023 | finance.yahoo.comTreace Medical Concepts Reports Second Quarter 2023 Financial ResultsSee More Headlines Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TMCI CUSIPN/A CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees423Year FoundedN/APrice Target and Rating Average Stock Price Target$18.92 High Stock Price Target$27.50 Low Stock Price Target$11.00 Potential Upside/Downside+117.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,810,000.00 Net Margins-27.28% Pretax Margin-27.28% Return on Equity-37.68% Return on Assets-21.22% Debt Debt-to-Equity Ratio0.38 Current Ratio5.64 Quick Ratio4.76 Sales & Book Value Annual Sales$141.84 million Price / Sales3.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book7.96Miscellaneous Outstanding Shares61,680,000Free Float43,981,000Market Cap$535.38 million OptionableNot Optionable Beta0.17 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. John T. Treace (Age 51)CEO, Founder & Director Comp: $1.04MMr. Mark L. Hair CPA (Age 53)Chief Financial Officer Comp: $628.6kMr. Aaron J. Berutti (Age 44)Senior Vice President of Sales Comp: $519.41kMr. Terry W. Lubben (Age 58)Senior Vice President of Operations Ms. Julie D. Dewey (Age 62)Chief Communications & Investor Relations Officer Mr. Scot M. Elder (Age 48)Chief Legal & Compliance Officer and Corporate Secretary Mr. Nathan MinnichSenior Vice President of MarketingMr. Daniel E. Owens (Age 51)Chief Human Resources Officer Mr. Jaime A. Frias (Age 61)Chief Business Development Officer Comp: $271.04kDr. Sean F. Scanlan Ph.D. (Age 40)Chief Innovation Officer More ExecutivesKey CompetitorsOraSure TechnologiesNASDAQ:OSURAtrionNASDAQ:ATRIIRadimedNASDAQ:IRMDPulse BiosciencesNASDAQ:PLSENevroNYSE:NVROView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 348,893 shares on 11/24/2023Ownership: 0.036%Walleye Capital LLCBought 88,239 shares on 11/21/2023Ownership: 0.227%TimesSquare Capital Management LLCBought 584,539 shares on 11/17/2023Ownership: 2.324%Creative PlanningBought 1,495 shares on 11/16/2023Ownership: 0.033%Spouting Rock Asset Management LLCBought 11,260 shares on 11/16/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions TMCI Stock Analysis - Frequently Asked Questions Should I buy or sell Treace Medical Concepts stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMCI shares. View TMCI analyst ratings or view top-rated stocks. What is Treace Medical Concepts' stock price target for 2024? 6 Wall Street analysts have issued 12 month price objectives for Treace Medical Concepts' shares. Their TMCI share price targets range from $11.00 to $27.50. On average, they predict the company's stock price to reach $18.92 in the next year. This suggests a possible upside of 108.1% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts. How have TMCI shares performed in 2023? Treace Medical Concepts' stock was trading at $22.99 at the beginning of 2023. Since then, TMCI stock has decreased by 60.5% and is now trading at $9.09. View the best growth stocks for 2023 here. When is Treace Medical Concepts' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our TMCI earnings forecast. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) posted its earnings results on Thursday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The business had revenue of $40.76 million for the quarter, compared to analyst estimates of $42.08 million. Treace Medical Concepts had a negative net margin of 27.28% and a negative trailing twelve-month return on equity of 37.68%. When did Treace Medical Concepts IPO? (TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. Who are Treace Medical Concepts' major shareholders? Treace Medical Concepts' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (2.90%), Emerald Advisers LLC (2.39%), TimesSquare Capital Management LLC (2.32%), Emerald Mutual Fund Advisers Trust (1.94%), Loomis Sayles & Co. L P (1.83%) and Kornitzer Capital Management Inc. KS (1.10%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie. View institutional ownership trends. How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TMCI) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.